Chromocell Therapeutics

Yahoo Finance • 3 months ago

Channel Therapeutics Announces 10-for-1 Reverse Split, $50 Mln Placement

(RTTNews) - Channel Therapeutics Corp. (CHRO) announced Friday a 10-for-1 reverse stock split in connection with the closing of its merger with Pelthos Therapeutics and a concurrent $50.1 million private placement. The reverse stock split... Full story

Yahoo Finance • 3 months ago

Channel Therapeutics announces 10-for-1 reverse stock split

FREEHOLD, N.J. - Channel Therapeutics Corporation (NYSE American:CHRO), currently trading at $1.17 with a market capitalization of $7.72 million, announced a 10-for-1 reverse stock split of its common stock, scheduled to take effect before... Full story

Yahoo Finance • 3 months ago

MAIA Biotechnology, Roche sign supply agreement for cancer therapies

MAIA Biotechnology (MAIA) announced its entry into a clinical master supply agreement with Roche (RHHBY) for future studies. The agreement will investigate the combination of MAIA’s telomere-targeting agent ateganosine, sequenced with Roch... Full story